Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "accounting"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
language:"English"
Showing
1
-
20
of
36
Search:
'"accounting"'
,
query time: 0.04s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Canakinumab (Ilaris)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
... onset JIA (sJIA) is a subtype of the disease
accounting
for approximately 4% to 15% of patients...
”
Read Now
2
Canakinumab (Ilaris)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
... onset JIA (sJIA) is a subtype of the disease
accounting
for approximately 4% to 15% of patients...
”
Read Now
3
Technologies assisting in remote consultations for the diagnosis of stroke : a review of the clinical evidence
Published 2013
Canadian Agency for Drugs and Technologies in Health
Read Now
4
Sapropterin dihydrochloride (Kuvan)
Published 2017
CADTH
“
... in approximately one in every 12,000 to 15,000 infants born in North America,
accounting
for approximately 300 new...
”
Read Now
5
Sapropterin dihydrochloride (Kuvan)
Published 2017
CADTH
“
... in approximately one in every 12,000 to 15,000 infants born in North America,
accounting
for approximately 300 new...
”
Read Now
6
Blue light cystoscopy in patients with suspected non-muscle invasive bladder carcinoma: a review of clinical utility
by
Tran, Khai
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...According to Canadian Cancer Statistics, bladder cancer is the fifth most common cancer,
accounting
...
”
Read Now
7
Pharmacoeconomic review report: Iron isomaltoside 1000 (Monoferric) (Pharmacosmos A/S) : indication: for the treatment of iron deficiency anemia in adult patients who have intolera...
Published 2020
CADTH
Read Now
8
Blue light cystoscopy in patients with suspected non-muscle invasive bladder carcinoma: a review of clinical utility
by
Tran, Khai
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...According to Canadian Cancer Statistics, bladder cancer is the fifth most common cancer,
accounting
...
”
Read Now
9
Pharmacoeconomic review report: Iron isomaltoside 1000 (Monoferric) (Pharmacosmos A/S) : indication: for the treatment of iron deficiency anemia in adult patients who have intolera...
Published 2020
CADTH
Read Now
10
Aflibercept (Eylea) : treatment of neovascular (wet) age-related macular degeneration (wAMD)
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
... and neovascular (wet) AMD (wAMD). While wAMD develops in only 10% to 20% of people with dry AMD, it
accounts
...
”
Read Now
11
Aflibercept (Eylea) : treatment of neovascular (wet) age-related macular degeneration (wAMD)
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
... and neovascular (wet) AMD (wAMD). While wAMD develops in only 10% to 20% of people with dry AMD, it
accounts
...
”
Read Now
12
Optimal warfarin management for prevention of thromboembolic events in patients with atrial fibrillation
Published 2011
Canadian Agency for Drugs and Technologies in Health
Read Now
13
Pharmacoeconomic report: Apomorphine hydrochloride (Kynmobi) (Sunovion Pharmaceuticals Canada Inc.) : indication: the acute, intermittent treatment of "OFF" episodes in patients wi...
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
... uncertainties remain, as the model did not
account
for the need for subsequent or adjunctive treatments...
”
Read Now
14
The use of the electromotive drug administration system in patients with superficial bladder cancer : a review of the clinical effectiveness, safety, and cost-effectiveness
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
...Non-muscle (superficial) invasive bladder cancer
accounted
for about 6% of all cancers in Canada...
”
Read Now
15
The use of the electromotive drug administration system in patients with superficial bladder cancer : a review of the clinical effectiveness, safety, and cost-effectiveness
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
...Non-muscle (superficial) invasive bladder cancer
accounted
for about 6% of all cancers in Canada...
”
Read Now
16
Wear compliance and donning/doffing of respiratory protection for bioaerosols or infectious agents : a review of the effectiveness, safety, and guidelines
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
... which
account
for 99,000 deaths. Proper use of respiratory protection is a critical part of the process...
”
Read Now
17
Pharmacoeconomic report: Vedolizumab (Entyvio SC) Takeda Canada Inc. : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis who ha...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... populations as distinct populations. CADTH also
accounted
for limitations by including relevant comparators...
”
Read Now
18
Wear compliance and donning/doffing of respiratory protection for bioaerosols or infectious agents : a review of the effectiveness, safety, and guidelines
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
... which
account
for 99,000 deaths. Proper use of respiratory protection is a critical part of the process...
”
Read Now
19
Pharmacoeconomic report: Vedolizumab (Entyvio SC) Takeda Canada Inc. : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis who ha...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... populations as distinct populations. CADTH also
accounted
for limitations by including relevant comparators...
”
Read Now
20
Axicabtagene ciloleucel for large B-cell lymphoma: Health technology assessment introduction and clinical review protocol
Published 2019
Canadian Agency for Drugs and Technologies in Health
“
..., NHL
accounts
for 83% of all cases of lymphomas. In this context, axicabtagene ciloleucel is a chimeric...
”
1
2
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
610 - Medicine & health
20
330 - Economics
8
700 - The arts; fine & decorative arts
6
140 - Specific philosophical schools
3
576 - Genetics & evolution
2
600 - Technology
2
Language
English
Collection
National Center for Biotechnology Information
36
Author
Canadian Agency for Drugs and Technologies in Health
Severn, Melissa
2
Tran, Khai
2
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=language%3A%22English%22&lookfor=%22accounting%22&type=AllFields
Send by Email
×
Loading...